Dobutamine HCl
产品说明书
 |
同义名 : | Dobutamine (hydrochloride); Dobutrex; NSC 299583; Inotrex; Dobutamine hydrochloride |
| CAS号 : | 49745-95-1 | |
| 货号 : | A192909 | |
| 分子式 : | C18H24ClNO3 | |
| 纯度 : | 99% | |
| 分子量 : | 337.84 | |
| MDL号 : | MFCD13185823 | |
| 存储条件： |
Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Dobutamine HCl is a synthetic catecholamine that acts on alpha-1, beta-1 and beta-2 adrenergic receptors. In clinical use, dobutamine has a rapid onset of action and a short half-life[3]. Dobutamine has the capacity to stimulate beta 1-, beta 2-, and alpha 1-adrenoceptors in the cardiovascular system at doses that approximate those used clinically. Furthermore, in the vasculature, the beta 2-adrenoceptor-mediated vasodilatory effect of dobutamine is exactly offset by the alpha 1-adrenoceptor-mediated vasoconstrictor activity, such that net changes in blood pressure are minimal following the administration of dobutamine[4]. Dobutamine increased the contractility of isolated cat papillary muscles more but the automaticity less than did isoproterenol. In ischemic dog hearts, dobutamine lacked significant arrhythmic activity, whereas dopamine, norepinephrine, and isoproterenol caused severe ectopic activity[5]. Dobutamine hydrochloride (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice. Dobutamine hydrochloride results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice. In the Tgαq*44 mice low doses of dobutamine significantly increased inotropic and lusitropic cardiac performance without chronotropic changes. An increased heart rate was observed only after high doses of dobutamine, but then inotropic and lusitropic cardiac functional reserve was lost[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00001314 | - | Completed | - | United States, Maryland ... 展开 >> National Heart, Lung and Blood Institute (NHLBI) Bethesda, Maryland, United States, 20892 收起 << | |
| NCT00338455 | Congestive Heart Failure ... 展开 >> Cardiac Transplantation Renal Insufficiency Renal Failure 收起 << | Phase 2 | Terminated(DSMC acknowledged n... 展开 >>o safety concerns with the trial, recommending that the trial be terminated due to slow enrollment) 收起 << | - | United States, California ... 展开 >> Stanford, California, United States United States, Florida Tampa, Florida, United States United States, Illinois Chicago, Illinois, United States Maywood, Illinois, United States United States, Maryland Baltimore, Maryland, United States United States, Massachusetts Boston, Massachusetts, United States United States, Missouri Saint Louis, Missouri, United States United States, New York New York, New York, United States United States, Ohio Cleveland, Ohio, United States Columbus, Ohio, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, South Carolina Charleston, South Carolina, United States United States, Texas Houston, Texas, United States United States, Washington Seattle, Washington, United States 收起 << |
| NCT00791843 | Congestive Heart Failure | Phase 2 | Completed | - | United States, Massachusetts ... 展开 >> Massachusetts General Hospital/ Geriatric Research Boston, Massachusetts, United States, 02114 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.96mL 0.59mL 0.30mL |
14.80mL 2.96mL 1.48mL |
29.60mL 5.92mL 2.96mL |
| 参考文献 |
|---|
|
[4]Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987;294(4):244-248 |